Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 1/20 | 0.42 |
| ▸ | ACHE | P22303 | 3/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.35 |
| ▸ | NCEH1 | Q6PIU2 | 1/20 | 0.34 |
| ▸ | MEN1 | O00255 | 2/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.34 |
| ▸ | GAA | P10253 | 2/20 | 0.34 |
| ▸ | MAPT | P10636 | 2/20 | 0.33 |
| ▸ | PRMT5 | O14744 | 1/20 | 0.33 |
| ▸ | POLB | P06746 | 1/20 | 0.33 |
| ▸ | HTT | P42858 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12426433 | 0.82 | TSHR (0.45) | TSHRACHEALDH1A1KDM4ENCEH1 | |
| SCHEMBL12426443 | 0.80 | TSHR (0.43) | TSHRACHEALDH1A1KDM4ENCEH1 | |
| SCHEMBL12426432 | 0.79 | ACHE (0.58) | TSHRACHEALDH1A1KDM4EMEN1 | |
| SCHEMBL12426434 | 0.74 | TSHR (0.37) | TSHRACHEALDH1A1HTT | |
| SCHEMBL12426441 | 0.68 | TSHR (0.41) | TSHRACHEALDH1A1KDM4EMEN1 | |
| SCHEMBL12426431 | 0.67 | TSHR (0.39) | TSHRACHEALDH1A1KDM4ENCEH1 | |
| SCHEMBL11771539 | 0.65 | NCEH1 (0.46) | TSHRALDH1A1NCEH1HTT | |
| SCHEMBL2198922 | 0.65 | TSHR (0.61) | TSHRALDH1A1NCEH1 | |
| SCHEMBL11488474 | 0.64 | TSHR (0.51) | TSHRALDH1A1NCEH1MEN1KMT2A | |
| SCHEMBL12426444 | 0.64 | TSHR (0.43) | TSHRACHEMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7977354-B2 | Heterocyclic compounds, their preparation and their use as medicaments, in particular as anti-alzheimer agents | INSA ROUEN (FR) | 2011-07-12 | — | — | US | disclosed |
| US-20090062279-A1 | HETEROCYCLIC COMPOUNDS, THEIR PREPARATION AND THEIR USE AS MEDICAMENTS, IN PARTICULAR AS ANTI-ALZHEIMER AGENTS | INSA ROUEN (FR) | 2009-03-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090062279-A1 | HETEROCYCLIC COMPOUNDS, THEIR PREPARATION AND THEIR USE AS MEDICAMENTS, IN PARTICULAR AS ANTI-ALZHEIMER AGENTS | NLN, SNCA, APP | TSHR 4786/4885ACHE 17/4885ALDH1A1 1663/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.